CARE™ Presents

Hematology Update

Hematology

29 Sep 2021

Updates in Hematology

CARE™ has been busy! See below the recent work from the CARE™ Hematology Faculty, featuring Discussion Video Series & Guidances.

CARE™ CLL Case Study Series – Issue 4, Part 2:
Successful Initiation Of Venetoclax (Ven) + Rituximab (R) In Outpatient Setting
  • This is a continuation of the case study presented in the 4th issue of the CARE™ CLL Case Series: Successful Initiation Of Venetoclax (Ven) + Rituximab (R) In Outpatient Setting.

  • We were pleased to have Dr. Carolyn Owen (University of Calgary) sit down with Dr. Laurie Sehn (BC Cancer) who took a deeper look at the case and discussed the use of venetoclax and rituximab in routine practice.

CARE™ CLL Discussion Series:
PART 1: Long-Term Data and Safety Updates with BTKi’s
  • CARE™ Hematology Faculty members, Dr. John Kuruvilla (Princess Margaret Cancer) and Peter Anglin (Stronach Reginal Cancer Centre) hosted internationally renowned experts, Dr. Susan O’Brien (Chao Family Comprehensive Cancer Centre, California) and John Pagel (Swedish Cancer Centre, Washington).
  • This issue covers challenges and controversies in CLL, particularly related to management of patients that we’re seeing day-to-day in the clinic and informed by recent data that have been presented in recent months from major international meetings.

CARE™ Guidance: Integration of CAR T in DLBCL
  • The aim of this guidance is to provide education on(chimeric antigen receptor T-cell therapy (CAR T) options and considerations for effective integration of these therapies in Canadian practice, with emphasis on where CAR T fits in current paradigms, candidates for CAR T referral and post treatment monitoring and adverse event management.

ASCO/EHA On-Demand Sessions
  • Leading Canadian hematologists contextualized key news and data from both the ASCO & EHA 2021 Conferences framing the news from a Canadian perspective virtually on Wednesday, June 16th 2021.

  • The presentations are available 0n-demand!
MM Guidance
  • In July 2020, The CARE™ Hematology Faculty developed and published Considerations for Malignant Hematology Patient Management and Treatment During the COVID-19 Era.

  • Changes in the delivery of care brought on by the pandemic have happened fast, despite not necessarily being optimal for patient outcomes. These changes, as well as increased complexity with MM treatment decisions with availability of novel agents have prompted the CARE™ Faculty to create the CARE™ MM Treatment Guidance: Navigating the New Normal in 2021.

CLL Guidance
  • In July 2020, The CARE™ Hematology Faculty developed and published Considerations for Malignant Hematology Patient Management and Treatment During the COVID-19 Era.

  • Changes in the delivery of care brought on by the pandemic have happened fast, despite not necessarily being optimal for patient outcomes. These changes, as well as recent drug approvals have prompted the CARE™ Faculty to update the CARE™ CLL Treatment Guidance; first developed and distributed in 2018.